Connect Biopharma Holdings reported revenue of $2.77M and net income of -$17.28M for the quarter ended Jun 2026. This income statement covers 16 quarters of results from Dec 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2020 | Dec2021 | Jun2022 | Dec2022 | Jun2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 19.65M | 55.08M | 55.04M | 55.10M | 55.01M | 55.25M | 55.25M | 55.35M | 55.35M | 55.58M | 55.79M | 56.44M | 62.71M | 62.97M | ||
| Revenue & cost | ||||||||||||||||
| Revenue | 1.22M | 0.70M | 0.05M | 0.02M | 0.17M | 2.77M | ||||||||||
| Operating items | ||||||||||||||||
| Research & DevelopmentR&D | 8.66M | 5.35M | 9.01M | 6.24M | 6.63M | 8.77M | 11.11M | 11.28M | 15.03M | 16.27M | ||||||
| Selling, General & AdministrativeSG&A | 3.97M | 5.12M | 6.06M | 4.08M | 4.81M | 4.70M | 6.58M | 4.24M | 4.75M | 4.10M | ||||||
| Operating ExpensesOpex | 12.63M | 10.47M | 15.06M | 10.32M | 11.45M | 13.47M | 17.69M | 15.53M | 19.78M | 20.37M | ||||||
| Operating IncomeOp. Inc | -12.63M | 13.65M | -13.85M | -9.62M | -11.45M | -13.42M | -17.68M | -15.53M | -19.61M | -17.60M | ||||||
| EBIT | -12.63M | 13.65M | -13.85M | -9.62M | -11.45M | -13.42M | -17.68M | -15.53M | -19.61M | -17.60M | ||||||
| Non-operating items | ||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 1.25M | 1.22M | 1.14M | 0.85M | 0.72M | 0.62M | 0.55M | 0.38M | 0.26M | 0.31M | ||||||
| Other Non Operating IncomeOther Non Op Inc. | 2.72M | 0.01M | -0.11M | -0.03M | 0.51M | -0.04M | -0.01M | 0.06M | -0.00M | 0.07M | ||||||
| Non Operating IncomeNon Op. Inc. | 3.97M | 1.23M | 1.03M | 0.82M | 1.23M | 0.58M | 0.54M | 0.44M | 0.26M | 0.38M | ||||||
| Net income details | ||||||||||||||||
| EBT | -8.66M | 14.88M | -12.82M | -8.80M | -10.22M | -12.84M | -17.14M | -15.08M | -19.35M | -17.22M | ||||||
| Tax ProvisionsTaxes | 0.03M | 0.03M | 0.06M | 0.11M | 0.05M | 0.06M | 0.06M | 0.03M | 0.05M | 0.06M | ||||||
| Profit After TaxPAT | -8.69M | 14.85M | -12.88M | -9.56M | -10.27M | -12.90M | -17.20M | -15.11M | -19.40M | -17.28M | ||||||
| Income from Continuing OperationsIncome (Continuing) | -8.69M | 14.85M | -12.88M | -8.91M | -10.27M | -12.90M | -17.20M | -15.11M | -19.40M | -17.28M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -8.69M | 14.85M | -12.88M | -8.91M | -10.27M | -12.90M | -17.20M | -15.11M | -19.40M | -17.28M | ||||||
| Income towards Parent CompanyParent Net Inc | -8.69M | 14.85M | -12.88M | -8.91M | -10.27M | -12.90M | -17.20M | -15.11M | -19.40M | -17.28M | ||||||
| Net Income towards Common StockholdersNet Income | -8.69M | 14.85M | -12.88M | -8.91M | -10.27M | -12.90M | -17.20M | -15.11M | -19.40M | -17.28M | ||||||
| Additional items | ||||||||||||||||
| EPS (Basic) | -0.16 | 0.27 | -0.23 | -0.16 | -0.19 | -0.23 | -0.31 | -0.27 | -0.34 | -0.27 | ||||||
| EPS (Diluted) | -0.16 | 0.27 | -0.23 | -0.16 | -0.19 | -0.23 | -0.31 | -0.27 | -0.34 | -0.27 | ||||||
| Shares Outstanding | 17.09M | 52.18M | 52.18M | 55.04M | 55.04M | 55.07M | 55.10M | 55.19M | 55.25M | 55.21M | 55.35M | 55.50M | 55.72M | 55.66M | 56.55M | 62.88M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 55.07M | 55.10M | 55.71M | 55.25M | 55.21M | 55.35M | 55.50M | 55.72M | 55.66M | 56.55M | 62.88M | |||||
| EBITDA | -12.63M | 13.65M | -13.85M | -9.62M | -11.45M | -13.42M | -17.68M | -15.53M | -19.61M | -17.60M | ||||||
| Tax Rate | -0.35 | 0.20 | -0.44 | -1.20 | -0.53 | -0.43 | -0.36 | -0.18 | -0.25 | -0.35 |